Glycoprotein News and Research

RSS

SARS-CoV-2 spike protein mediates acute lung pathology in mice

A study shows that the viral spike protein is adequate by itself to induce macrophage activation in pulmonary tissue and induce acute inflammation.

10 Dec 2020

Different SARS-CoV-2 neutralization assays are reliable and concordant for antibody monitoring

A recent study by US researchers, currently available on the medRxiv preprint server, evaluated several cell-based assays that are under validation for determining correlates of protection in individuals with symptomatic coronavirus disease (COVID-19) and vaccine studies – and demonstrated their high concordance with both live and pseudotyped virions.

9 Dec 2020

Mount Sinai study shows strong immune response, durability of universal influenza virus vaccine

A vaccine that induces immune responses to a wide spectrum of influenza virus strains and subtypes has produced strong and durable results in early-stage clinical trials in humans, Mount Sinai researchers have found.

7 Dec 2020

High-performance ELISA for serology in mild-moderate non-hospitalized COVID-19

A new study describes an ELISA assay that combines the detection of IgM, IgA, and IgG antibodies against the SARS−CoV−2 trimeric spike glycoprotein.

7 Dec 2020

Can melatonin help prevent severe COVID-19?

A team of researchers at the University of Toronto in Canada has found that melatonin can be an adjuvant to augment the efficacy of anti-SARS-CoV-2 vaccines. They believe that the drug is a potential “silver bullet” to combat the COVID-19 pandemic.

3 Dec 2020

COVID-19 mutation mapping identifies escape mutations against therapeutic antibodies

A new study maps all known mutations in the SARS-CoV-2 virus, showing how each contributes to escape from individual antibodies.

3 Dec 2020

Novel “multitope” vaccine shows promise in the fight against COVID-19

Researchers have demonstrated the potential of a protein-peptide vaccine to protect against infection with SARS-CoV-2, the agent that causes COVID-19.

3 Dec 2020

Spanish-originated SARS-CoV-2 variant A222V shows rapid spread in Lazio, Italy

A startling new study reports the rapid rise to dominance of a new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strain in Italy. This strain, termed the GV clade, is characterized by a single point mutation.

2 Dec 2020

A mutant SARS-CoV-2 subspecies from minks may evade antibody detection

In a recent research letter published on the bioRxiv preprint server, scientists from Japan discovered that the mutation of spike glycoprotein in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) derived from farmed minks can also be found in the group of individuals with coronavirus disease (COVID-19) and subsequently evade detection by our immune system.

30 Nov 2020

Steam inhalation therapy found to inactivate SARS-CoV-2 virions

Researchers have published a study on the efficacy of steam inhalations as another possible treatment to help mitigate SARS-CoV-2 infection.

30 Nov 2020

Study exposes human olfactory and brain cells as genuine viral targets of SARS-CoV-2

In a study published in the iScience journal, a research group from Switzerland shows that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptors and entry genes are expressed in the human olfactory neuroepithelial cells and brain by observing key molecular players implicated in the infectious process

29 Nov 2020

Early interferon therapy may mitigate COVID-19 severity

A recent review of COVID-19 therapies explores the utility of interferons in the battle against severe COVID-19, and concludes that they deserve further development.

26 Nov 2020

Inhibiting SARS-CoV-2 cell entry with monoclonal antibodies against staphylococcal enterotoxin B superantigen

In a recent cutting-edge study, US researchers unveiled an anti-staphylococcal enterotoxin B monoclonal antibody that can be repurposed to target the cleavage site of the SARS-CoV-2 spike glycoprotein and, in turn, inhibit viral infection. Their findings are currently available on bioRxiv preprint server.

25 Nov 2020

Biosensor assay SARS-CoV-2 antibody test may predict COVID-19 severity in patients

Researchers in New York, USA, have found an association of mortality with an early humoral response to SARS-CoV-2 infection within the first few days after onset of symptoms (DAOS), using a highly sensitive and automated testing-on-a-probe (TOP) biosensor assays for SARS-CoV-2.

24 Nov 2020

SARS-CoV-2's spike protein mutations have slowed, study finds

A team of researchers at the School of Information Sciences in Illinois, USA, has revealed the rate of mutation in the 29 proteins that make up the SARS-CoV-2 microbe.

23 Nov 2020

SARS-CoV-2 spike deletion mutations may evade current vaccine candidates, study finds

A thought-provoking new study reports that the anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike antibodies elicited by natural infection may not be able to neutralize emerging strains that display deletion mutations in their genomic RNA.

23 Nov 2020

Pomegranate peel extract shows potential as inhibitor of SARS-CoV-2 virus

Researchers led by first author Relja Suručić from the Department of Pharmacognosy, Faculty of Medicine, University of Banja Luka, Banja Luka, Bosnia and Herzegovina, have studied the use of pomegranate peel extracts in preventing infections with SARS-CoV-2.

22 Nov 2020

Furin inhibition may mitigate severe COVID-19, study finds

Dr. Kara Fitzgerald, a researcher at the Institute for Functional Medicine in the United States, has explained the role of furin protease in developing severe COVID-19 illness.

20 Nov 2020

Genetic variations of SARS-CoV-2 transmission in cats

Using cats as an animal model to study severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission, researchers have determined the virus has a narrow transmission bottleneck.

19 Nov 2020

Asymptomatic individuals mount polyfunctional antibody response to SARS-CoV-2

Researchers in France have conducted a study showing that people who are asymptomatic following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – elicit a polyfunctional antibody response to the virus.

16 Nov 2020